ARCHIVES

FDA Grants Priority Review To Two Drugs in NSCLC

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

Bepler To Lead Karmanos Cancer Institute

January 29, 2010

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008

NCAB Task Force Urges New Study Section For Clinical Cancer Research, Sees “Crisis”

May 7, 1993

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Schering to Pay $435M to Settle Federal Charges.

January 26, 2007

Breast Cancers Detected By Mammograms Have Better Prognosis, Trials Analysis Finds

September 30, 2005